Global Cell-based Flu Vaccine Market Research Report 2023

Cell-based Flu Vaccine Market

The global Cell-based Flu Vaccine market was valued at US$ million in 2022 and is anticipated to reach US$ million by 2029, witnessing a CAGR of % during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.

North American market for Cell-based Flu Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

Asia-Pacific market for Cell-based Flu Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.

The key global manufacturers of Cell-based Flu Vaccine include GlaxoSmithKline, Sanofi, Pfizer, MedImmune, LLC, Intravacc, CSL Limited, E. Merck KG, Novartis and Danaher Corporation, etc. in 2022, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Cell-based Flu Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Cell-based Flu Vaccine.

The Cell-based Flu Vaccine market size, estimations, and forecasts are provided in terms of sales volume (M Doses) and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Cell-based Flu Vaccine market comprehensively. Regional market sizes, concerning products by type, by application and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Cell-based Flu Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by type, by application and by regions.

Scope of Cell-based Flu Vaccine Market Report

Core Chapters

1.1 Product Overview and Scope of Cell-based Flu Vaccine

1.2 Cell-based Flu Vaccine Segment by Type

1.2.1 Global Cell-based Flu Vaccine Market Value Comparison by Type (2023-2029)

1.2.2 Trivalent Influenza Vaccine

1.2.3 Quadrivalent Influenza Vaccine

1.3 Cell-based Flu Vaccine Segment by Application

1.3.1 Global Cell-based Flu Vaccine Market Value by Application: (2023-2029)

1.3.2 Aldults

1.3.3 Children

1.4 Global Cell-based Flu Vaccine Market Size Estimates and Forecasts

1.4.1 Global Cell-based Flu Vaccine Revenue 2018-2029

1.4.2 Global Cell-based Flu Vaccine Sales 2018-2029

1.4.3 Global Cell-based Flu Vaccine Market Average Price (2018-2029)

1.5 Assumptions and Limitations

2.1 Global Cell-based Flu Vaccine Sales Market Share by Manufacturers (2018-2023)

2.2 Global Cell-based Flu Vaccine Revenue Market Share by Manufacturers (2018-2023)

2.3 Global Cell-based Flu Vaccine Average Price by Manufacturers (2018-2023)

2.4 Global Cell-based Flu Vaccine Industry Ranking 2021 VS 2022 VS 2023

2.5 Global Key Manufacturers of Cell-based Flu Vaccine, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Cell-based Flu Vaccine, Product Type & Application

2.7 Cell-based Flu Vaccine Market Competitive Situation and Trends

2.7.1 Cell-based Flu Vaccine Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Cell-based Flu Vaccine Players Market Share by Revenue

2.7.3 Global Cell-based Flu Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3.1 Global Cell-based Flu Vaccine Market Size by Region: 2018 Versus 2022 Versus 2029

3.2 Global Cell-based Flu Vaccine Global Cell-based Flu Vaccine Sales by Region: 2018-2029

3.2.1 Global Cell-based Flu Vaccine Sales by Region: 2018-2023

3.2.2 Global Cell-based Flu Vaccine Sales by Region: 2024-2029

3.3 Global Cell-based Flu Vaccine Global Cell-based Flu Vaccine Revenue by Region: 2018-2029

3.3.1 Global Cell-based Flu Vaccine Revenue by Region: 2018-2023

3.3.2 Global Cell-based Flu Vaccine Revenue by Region: 2024-2029

3.4 North America Cell-based Flu Vaccine Market Facts & Figures by Country

3.4.1 North America Cell-based Flu Vaccine Market Size by Country: 2018 VS 2022 VS 2029

3.4.2 North America Cell-based Flu Vaccine Sales by Country (2018-2029)

3.4.3 North America Cell-based Flu Vaccine Revenue by Country (2018-2029)

3.4.4 U.S.

3.4.5 Canada

3.5 Europe Cell-based Flu Vaccine Market Facts & Figures by Country

3.5.1 Europe Cell-based Flu Vaccine Market Size by Country: 2018 VS 2022 VS 2029

3.5.2 Europe Cell-based Flu Vaccine Sales by Country (2018-2029)

3.5.3 Europe Cell-based Flu Vaccine Revenue by Country (2018-2029)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Cell-based Flu Vaccine Market Facts & Figures by Country

3.6.1 Asia Pacific Cell-based Flu Vaccine Market Size by Country: 2018 VS 2022 VS 2029

3.6.2 Asia Pacific Cell-based Flu Vaccine Sales by Country (2018-2029)

3.6.3 Asia Pacific Cell-based Flu Vaccine Revenue by Country (2018-2029)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.6.13 Philippines

3.7 Latin America Cell-based Flu Vaccine Market Facts & Figures by Country

3.7.1 Latin America Cell-based Flu Vaccine Market Size by Country: 2018 VS 2022 VS 2029

3.7.2 Latin America Cell-based Flu Vaccine Sales by Country (2018-2029)

3.7.3 Latin America Cell-based Flu Vaccine Revenue by Country (2018-2029)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Cell-based Flu Vaccine Market Facts & Figures by Country

3.8.1 Middle East and Africa Cell-based Flu Vaccine Market Size by Country: 2018 VS 2022 VS 2029

3.8.2 Middle East and Africa Cell-based Flu Vaccine Sales by Country (2018-2029)

3.8.3 Middle East and Africa Cell-based Flu Vaccine Revenue by Country (2018-2029)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 U.A.E

4.1 Global Cell-based Flu Vaccine Sales by Type (2018-2029)

4.1.1 Global Cell-based Flu Vaccine Sales by Type (2018-2023)

4.1.2 Global Cell-based Flu Vaccine Sales by Type (2024-2029)

4.1.3 Global Cell-based Flu Vaccine Sales Market Share by Type (2018-2029)

4.2 Global Cell-based Flu Vaccine Revenue by Type (2018-2029)

4.2.1 Global Cell-based Flu Vaccine Revenue by Type (2018-2023)

4.2.2 Global Cell-based Flu Vaccine Revenue by Type (2024-2029)

4.2.3 Global Cell-based Flu Vaccine Revenue Market Share by Type (2018-2029)

4.3 Global Cell-based Flu Vaccine Price by Type (2018-2029)

5.1 Global Cell-based Flu Vaccine Sales by Application (2018-2029)

5.1.1 Global Cell-based Flu Vaccine Sales by Application (2018-2023)

5.1.2 Global Cell-based Flu Vaccine Sales by Application (2024-2029)

5.1.3 Global Cell-based Flu Vaccine Sales Market Share by Application (2018-2029)

5.2 Global Cell-based Flu Vaccine Revenue by Application (2018-2029)

5.2.1 Global Cell-based Flu Vaccine Revenue by Application (2018-2023)

5.2.2 Global Cell-based Flu Vaccine Revenue by Application (2024-2029)

5.2.3 Global Cell-based Flu Vaccine Revenue Market Share by Application (2018-2029)

5.3 Global Cell-based Flu Vaccine Price by Application (2018-2029)

6.1 GlaxoSmithKline

6.1.1 GlaxoSmithKline Corporation Information

6.1.2 GlaxoSmithKline Description and Business Overview

6.1.3 GlaxoSmithKline Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2018-2023)

6.1.4 GlaxoSmithKline Cell-based Flu Vaccine Product Portfolio

6.1.5 GlaxoSmithKline Recent Developments/Updates

6.2 Sanofi

6.2.1 Sanofi Corporation Information

6.2.2 Sanofi Description and Business Overview

6.2.3 Sanofi Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2018-2023)

6.2.4 Sanofi Cell-based Flu Vaccine Product Portfolio

6.2.5 Sanofi Recent Developments/Updates

6.3 Pfizer

6.3.1 Pfizer Corporation Information

6.3.2 Pfizer Description and Business Overview

6.3.3 Pfizer Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2018-2023)

6.3.4 Pfizer Cell-based Flu Vaccine Product Portfolio

6.3.5 Pfizer Recent Developments/Updates

6.4 MedImmune, LLC

6.4.1 MedImmune, LLC Corporation Information

6.4.2 MedImmune, LLC Description and Business Overview

6.4.3 MedImmune, LLC Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2018-2023)

6.4.4 MedImmune, LLC Cell-based Flu Vaccine Product Portfolio

6.4.5 MedImmune, LLC Recent Developments/Updates

6.5 Intravacc

6.5.1 Intravacc Corporation Information

6.5.2 Intravacc Description and Business Overview

6.5.3 Intravacc Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2018-2023)

6.5.4 Intravacc Cell-based Flu Vaccine Product Portfolio

6.5.5 Intravacc Recent Developments/Updates

6.6 CSL Limited

6.6.1 CSL Limited Corporation Information

6.6.2 CSL Limited Description and Business Overview

6.6.3 CSL Limited Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2018-2023)

6.6.4 CSL Limited Cell-based Flu Vaccine Product Portfolio

6.6.5 CSL Limited Recent Developments/Updates

6.7 E. Merck KG

6.6.1 E. Merck KG Corporation Information

6.6.2 E. Merck KG Description and Business Overview

6.6.3 E. Merck KG Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2018-2023)

6.4.4 E. Merck KG Cell-based Flu Vaccine Product Portfolio

6.7.5 E. Merck KG Recent Developments/Updates

6.8 Novartis

6.8.1 Novartis Corporation Information

6.8.2 Novartis Description and Business Overview

6.8.3 Novartis Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2018-2023)

6.8.4 Novartis Cell-based Flu Vaccine Product Portfolio

6.8.5 Novartis Recent Developments/Updates

6.9 Danaher Corporation

6.9.1 Danaher Corporation Corporation Information

6.9.2 Danaher Corporation Description and Business Overview

6.9.3 Danaher Corporation Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2018-2023)

6.9.4 Danaher Corporation Cell-based Flu Vaccine Product Portfolio

6.9.5 Danaher Corporation Recent Developments/Updates

6.10 SINOVAC

6.10.1 SINOVAC Corporation Information

6.10.2 SINOVAC Description and Business Overview

6.10.3 SINOVAC Cell-based Flu Vaccine Sales, Revenue and Gross Margin (2018-2023)

6.10.4 SINOVAC Cell-based Flu Vaccine Product Portfolio

6.10.5 SINOVAC Recent Developments/Updates

7.1 Cell-based Flu Vaccine Industry Chain Analysis

7.2 Cell-based Flu Vaccine Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Cell-based Flu Vaccine Production Mode & Process

7.4 Cell-based Flu Vaccine Sales and Marketing

7.4.1 Cell-based Flu Vaccine Sales Channels

7.4.2 Cell-based Flu Vaccine Distributors

7.5 Cell-based Flu Vaccine Customers

8.1 Cell-based Flu Vaccine Industry Trends

8.2 Cell-based Flu Vaccine Market Drivers

8.3 Cell-based Flu Vaccine Market Challenges

8.4 Cell-based Flu Vaccine Market Restraints

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

List of Tables

    Table 1. Global Cell-based Flu Vaccine Market Value Comparison by Type (2023-2029) & (US$ Million)

    Table 2. Global Cell-based Flu Vaccine Market Value Comparison by Application (2023-2029) & (US$ Million)

    Table 3. Global Cell-based Flu Vaccine Market Competitive Situation by Manufacturers in 2022

    Table 4. Global Cell-based Flu Vaccine Sales (M Doses) of Key Manufacturers (2018-2023)

    Table 5. Global Cell-based Flu Vaccine Sales Market Share by Manufacturers (2018-2023)

    Table 6. Global Cell-based Flu Vaccine Revenue (US$ Million) by Manufacturers (2018-2023)

    Table 7. Global Cell-based Flu Vaccine Revenue Share by Manufacturers (2018-2023)

    Table 8. Global Market Cell-based Flu Vaccine Average Price (US$/Dose) of Key Manufacturers (2018-2023)

    Table 9. Global Key Players of Cell-based Flu Vaccine, Industry Ranking, 2021 VS 2022 VS 2023

    Table 10. Global Key Manufacturers of Cell-based Flu Vaccine, Manufacturing Sites & Headquarters

    Table 11. Global Key Manufacturers of Cell-based Flu Vaccine, Product Type & Application

    Table 12. Global Key Manufacturers of Cell-based Flu Vaccine, Date of Enter into This Industry

    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

    Table 14. Global Cell-based Flu Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Cell-based Flu Vaccine as of 2022)

    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

    Table 16. Global Cell-based Flu Vaccine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 17. Global Cell-based Flu Vaccine Sales by Region (2018-2023) & (M Doses)

    Table 18. Global Cell-based Flu Vaccine Sales Market Share by Region (2018-2023)

    Table 19. Global Cell-based Flu Vaccine Sales by Region (2024-2029) & (M Doses)

    Table 20. Global Cell-based Flu Vaccine Sales Market Share by Region (2024-2029)

    Table 21. Global Cell-based Flu Vaccine Revenue by Region (2018-2023) & (US$ Million)

    Table 22. Global Cell-based Flu Vaccine Revenue Market Share by Region (2018-2023)

    Table 23. Global Cell-based Flu Vaccine Revenue by Region (2024-2029) & (US$ Million)

    Table 24. Global Cell-based Flu Vaccine Revenue Market Share by Region (2024-2029)

    Table 25. North America Cell-based Flu Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 26. North America Cell-based Flu Vaccine Sales by Country (2018-2023) & (M Doses)

    Table 27. North America Cell-based Flu Vaccine Sales by Country (2024-2029) & (M Doses)

    Table 28. North America Cell-based Flu Vaccine Revenue by Country (2018-2023) & (US$ Million)

    Table 29. North America Cell-based Flu Vaccine Revenue by Country (2024-2029) & (US$ Million)

    Table 30. Europe Cell-based Flu Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 31. Europe Cell-based Flu Vaccine Sales by Country (2018-2023) & (M Doses)

    Table 32. Europe Cell-based Flu Vaccine Sales by Country (2024-2029) & (M Doses)

    Table 33. Europe Cell-based Flu Vaccine Revenue by Country (2018-2023) & (US$ Million)

    Table 34. Europe Cell-based Flu Vaccine Revenue by Country (2024-2029) & (US$ Million)

    Table 35. Asia Pacific Cell-based Flu Vaccine Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)

    Table 36. Asia Pacific Cell-based Flu Vaccine Sales by Region (2018-2023) & (M Doses)

    Table 37. Asia Pacific Cell-based Flu Vaccine Sales by Region (2024-2029) & (M Doses)

    Table 38. Asia Pacific Cell-based Flu Vaccine Revenue by Region (2018-2023) & (US$ Million)

    Table 39. Asia Pacific Cell-based Flu Vaccine Revenue by Region (2024-2029) & (US$ Million)

    Table 40. Latin America Cell-based Flu Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 41. Latin America Cell-based Flu Vaccine Sales by Country (2018-2023) & (M Doses)

    Table 42. Latin America Cell-based Flu Vaccine Sales by Country (2024-2029) & (M Doses)

    Table 43. Latin America Cell-based Flu Vaccine Revenue by Country (2018-2023) & (US$ Million)

    Table 44. Latin America Cell-based Flu Vaccine Revenue by Country (2024-2029) & (US$ Million)

    Table 45. Middle East & Africa Cell-based Flu Vaccine Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 46. Middle East & Africa Cell-based Flu Vaccine Sales by Country (2018-2023) & (M Doses)

    Table 47. Middle East & Africa Cell-based Flu Vaccine Sales by Country (2024-2029) & (M Doses)

    Table 48. Middle East & Africa Cell-based Flu Vaccine Revenue by Country (2018-2023) & (US$ Million)

    Table 49. Middle East & Africa Cell-based Flu Vaccine Revenue by Country (2024-2029) & (US$ Million)

    Table 50. Global Cell-based Flu Vaccine Sales (M Doses) by Type (2018-2023)

    Table 51. Global Cell-based Flu Vaccine Sales (M Doses) by Type (2024-2029)

    Table 52. Global Cell-based Flu Vaccine Sales Market Share by Type (2018-2023)

    Table 53. Global Cell-based Flu Vaccine Sales Market Share by Type (2024-2029)

    Table 54. Global Cell-based Flu Vaccine Revenue (US$ Million) by Type (2018-2023)

    Table 55. Global Cell-based Flu Vaccine Revenue (US$ Million) by Type (2024-2029)

    Table 56. Global Cell-based Flu Vaccine Revenue Market Share by Type (2018-2023)

    Table 57. Global Cell-based Flu Vaccine Revenue Market Share by Type (2024-2029)

    Table 58. Global Cell-based Flu Vaccine Price (US$/Dose) by Type (2018-2023)

    Table 59. Global Cell-based Flu Vaccine Price (US$/Dose) by Type (2024-2029)

    Table 60. Global Cell-based Flu Vaccine Sales (M Doses) by Application (2018-2023)

    Table 61. Global Cell-based Flu Vaccine Sales (M Doses) by Application (2024-2029)

    Table 62. Global Cell-based Flu Vaccine Sales Market Share by Application (2018-2023)

    Table 63. Global Cell-based Flu Vaccine Sales Market Share by Application (2024-2029)

    Table 64. Global Cell-based Flu Vaccine Revenue (US$ Million) by Application (2018-2023)

    Table 65. Global Cell-based Flu Vaccine Revenue (US$ Million) by Application (2024-2029)

    Table 66. Global Cell-based Flu Vaccine Revenue Market Share by Application (2018-2023)

    Table 67. Global Cell-based Flu Vaccine Revenue Market Share by Application (2024-2029)

    Table 68. Global Cell-based Flu Vaccine Price (US$/Dose) by Application (2018-2023)

    Table 69. Global Cell-based Flu Vaccine Price (US$/Dose) by Application (2024-2029)

    Table 70. GlaxoSmithKline Corporation Information

    Table 71. GlaxoSmithKline Description and Business Overview

    Table 72. GlaxoSmithKline Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2023)

    Table 73. GlaxoSmithKline Cell-based Flu Vaccine Product

    Table 74. GlaxoSmithKline Recent Developments/Updates

    Table 75. Sanofi Corporation Information

    Table 76. Sanofi Description and Business Overview

    Table 77. Sanofi Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2023)

    Table 78. Sanofi Cell-based Flu Vaccine Product

    Table 79. Sanofi Recent Developments/Updates

    Table 80. Pfizer Corporation Information

    Table 81. Pfizer Description and Business Overview

    Table 82. Pfizer Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2023)

    Table 83. Pfizer Cell-based Flu Vaccine Product

    Table 84. Pfizer Recent Developments/Updates

    Table 85. MedImmune, LLC Corporation Information

    Table 86. MedImmune, LLC Description and Business Overview

    Table 87. MedImmune, LLC Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2023)

    Table 88. MedImmune, LLC Cell-based Flu Vaccine Product

    Table 89. MedImmune, LLC Recent Developments/Updates

    Table 90. Intravacc Corporation Information

    Table 91. Intravacc Description and Business Overview

    Table 92. Intravacc Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2023)

    Table 93. Intravacc Cell-based Flu Vaccine Product

    Table 94. Intravacc Recent Developments/Updates

    Table 95. CSL Limited Corporation Information

    Table 96. CSL Limited Description and Business Overview

    Table 97. CSL Limited Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2023)

    Table 98. CSL Limited Cell-based Flu Vaccine Product

    Table 99. CSL Limited Recent Developments/Updates

    Table 100. E. Merck KG Corporation Information

    Table 101. E. Merck KG Description and Business Overview

    Table 102. E. Merck KG Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2023)

    Table 103. E. Merck KG Cell-based Flu Vaccine Product

    Table 104. E. Merck KG Recent Developments/Updates

    Table 105. Novartis Corporation Information

    Table 106. Novartis Description and Business Overview

    Table 107. Novartis Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2023)

    Table 108. Novartis Cell-based Flu Vaccine Product

    Table 109. Novartis Recent Developments/Updates

    Table 110. Danaher Corporation Corporation Information

    Table 111. Danaher Corporation Description and Business Overview

    Table 112. Danaher Corporation Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2023)

    Table 113. Danaher Corporation Cell-based Flu Vaccine Product

    Table 114. Danaher Corporation Recent Developments/Updates

    Table 115. SINOVAC Corporation Information

    Table 116. SINOVAC Description and Business Overview

    Table 117. SINOVAC Cell-based Flu Vaccine Sales (M Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2018-2023)

    Table 118. SINOVAC Cell-based Flu Vaccine Product

    Table 119. SINOVAC Recent Developments/Updates

    Table 120. Key Raw Materials Lists

    Table 121. Raw Materials Key Suppliers Lists

    Table 122. Cell-based Flu Vaccine Distributors List

    Table 123. Cell-based Flu Vaccine Customers List

    Table 124. Cell-based Flu Vaccine Market Trends

    Table 125. Cell-based Flu Vaccine Market Drivers

    Table 126. Cell-based Flu Vaccine Market Challenges

    Table 127. Cell-based Flu Vaccine Market Restraints

    Table 128. Research Programs/Design for This Report

    Table 129. Key Data Information from Secondary Sources

    Table 130. Key Data Information from Primary Sources

List of Figures

    Figure 1. Product Picture of Cell-based Flu Vaccine

    Figure 2. Global Cell-based Flu Vaccine Market Value Comparison by Type (2023-2029) & (US$ Million)

    Figure 3. Global Cell-based Flu Vaccine Market Share by Type in 2022 & 2029

    Figure 4. Trivalent Influenza Vaccine Product Picture

    Figure 5. Quadrivalent Influenza Vaccine Product Picture

    Figure 6. Global Cell-based Flu Vaccine Market Value Comparison by Application (2023-2029) & (US$ Million)

    Figure 7. Global Cell-based Flu Vaccine Market Share by Application in 2022 & 2029

    Figure 8. Aldults

    Figure 9. Children

    Figure 10. Global Cell-based Flu Vaccine Revenue, (US$ Million), 2018 VS 2022 VS 2029

    Figure 11. Global Cell-based Flu Vaccine Market Size (2018-2029) & (US$ Million)

    Figure 12. Global Cell-based Flu Vaccine Sales (2018-2029) & (M Doses)

    Figure 13. Global Cell-based Flu Vaccine Average Price (US$/Dose) & (2018-2029)

    Figure 14. Cell-based Flu Vaccine Report Years Considered

    Figure 15. Cell-based Flu Vaccine Sales Share by Manufacturers in 2022

    Figure 16. Global Cell-based Flu Vaccine Revenue Share by Manufacturers in 2022

    Figure 17. The Global 5 and 10 Largest Cell-based Flu Vaccine Players: Market Share by Revenue in 2022

    Figure 18. Cell-based Flu Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022

    Figure 19. Global Cell-based Flu Vaccine Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Figure 20. North America Cell-based Flu Vaccine Sales Market Share by Country (2018-2029)

    Figure 21. North America Cell-based Flu Vaccine Revenue Market Share by Country (2018-2029)

    Figure 22. U.S. Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 23. Canada Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 24. Europe Cell-based Flu Vaccine Sales Market Share by Country (2018-2029)

    Figure 25. Europe Cell-based Flu Vaccine Revenue Market Share by Country (2018-2029)

    Figure 26. Germany Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 27. France Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 28. U.K. Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 29. Italy Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 30. Russia Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 31. Asia Pacific Cell-based Flu Vaccine Sales Market Share by Region (2018-2029)

    Figure 32. Asia Pacific Cell-based Flu Vaccine Revenue Market Share by Region (2018-2029)

    Figure 33. China Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 34. Japan Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 35. South Korea Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 36. India Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 37. Australia Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 38. Taiwan Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 39. Indonesia Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 40. Thailand Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 41. Malaysia Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 42. Philippines Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 43. Latin America Cell-based Flu Vaccine Sales Market Share by Country (2018-2029)

    Figure 44. Latin America Cell-based Flu Vaccine Revenue Market Share by Country (2018-2029)

    Figure 45. Mexico Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 46. Brazil Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 47. Argentina Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 48. Middle East & Africa Cell-based Flu Vaccine Sales Market Share by Country (2018-2029)

    Figure 49. Middle East & Africa Cell-based Flu Vaccine Revenue Market Share by Country (2018-2029)

    Figure 50. Turkey Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 51. Saudi Arabia Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 52. U.A.E Cell-based Flu Vaccine Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 53. Global Sales Market Share of Cell-based Flu Vaccine by Type (2018-2029)

    Figure 54. Global Revenue Market Share of Cell-based Flu Vaccine by Type (2018-2029)

    Figure 55. Global Cell-based Flu Vaccine Price (US$/Dose) by Type (2018-2029)

    Figure 56. Global Sales Market Share of Cell-based Flu Vaccine by Application (2018-2029)

    Figure 57. Global Revenue Market Share of Cell-based Flu Vaccine by Application (2018-2029)

    Figure 58. Global Cell-based Flu Vaccine Price (US$/Dose) by Application (2018-2029)

    Figure 59. Cell-based Flu Vaccine Value Chain

    Figure 60. Cell-based Flu Vaccine Production Process

    Figure 61. Channels of Distribution (Direct Vs Distribution)

    Figure 62. Distributors Profiles

    Figure 63. Bottom-up and Top-down Approaches for This Report

    Figure 64. Data Triangulation

    Figure 65. Key Executives Interviewed